A Phase 3, Multicenter, Four-week, Randomized, Double-blind, Placebo-Controlled, Parallel-group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic)
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 01 Sep 2017 Planned End Date changed from 1 Oct 2021 to 10 Oct 2021.
- 01 Sep 2017 Planned primary completion date changed from 1 Oct 2021 to 4 Oct 2021.
- 03 Aug 2017 Planned End Date changed from 31 Jan 2018 to 1 Oct 2021.